ArriVent BioPharma (AVBP): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

ArriVent BioPharma, Inc (AVBP) focuses on a single primary lung cancer drug, leveraging exclusive rights in the US. The growth trajectory for next year's EPS reflects current dynamics, with the latest value recorded as 6.50. While the company is developing a unique targeted therapy system, it faces fierce competition and the likelihood of a prolonged period of unprofitability.

AVBP: Prakiraan wutah bathi kanggo taun ngarep ArriVent Corp 21.02.2024 - 15.11.2026

ArriVent BioPharma, Inc. - rincian analitis lan metrik utama (AVBP)

- rega saham lan konsensus proyeksi valuasi:

Rega saham ArriVent|AVBP - Rata-rata rega prakiraan

- data kapitalisasi bursa:

Nilai pasar ArriVent|AVBP - Nilai Dipunlarasaken Utang lan Kas

- rincian nilai buku perusahaan:

Nilai Buku saben Saham ArriVent BioPharma|AVBP - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku arrivent.com|AVBP - Nilai Agregat Aset

- indikator total utang lan likuiditas perusahaan:

Utang marang Ekuitas ArriVent BioPharma, Inc|AVBP - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal ArriVent|AVBP - Gunggung kewajiban utang perusahaan|Utang marang nilai buku ArriVent BioPharma Inc|AVBP - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan ArriVent BioPharma|Likuiditas cepet arrivent.com

- informasi bathi lan kelipatan valuasi:

AVBP - Bathi perusahaan|Bathi mangsa ngarep ArriVent BioPharma, Inc|AVBP - Rasio rega pasar marang bathi resik|Prakiraan rega marang bathi ArriVent BioPharma, Inc|AVBP - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA ArriVent BioPharma Inc|AVBP - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) ArriVent BioPharma|AVBP - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan arrivent.com|AVBP - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep ArriVent BioPharma, Inc

- data pendapatan lan penerimaan dodolan:

AVBP - Pendapatan tahunan perusahaan|Prakiraan volume dodolan ArriVent BioPharma, Inc.|AVBP - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S ArriVent BioPharma, Inc.|AVBP - Wutah dodolan YoY (TTM)

Analisis wiwitan perusahaan:ArriVent BioPharma, Inc

ArriVent BioPharma, Inc (AVBP) minimizes regulatory risks through the diversification of its oncology programs across the US and Asia, which directly impacts the projected forward-looking growth of earnings per share. This chart measures the amplitude of institutional expectation swings, allowing investors to use the metric's daily volatility to timely recognize revisions in the asset's fundamental value and avoid deep capital drawdowns.

Pesaing wigati

LTRN (Lantern Pharma Inc) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep bioaffinitytech.com BIAF|Prakiraan wutah bathi resik saben saham kanggo taun ngarep eEFFECTOR Therapeutics (EFTR)